Functional interaction between the HIV-1 Tat transactivator and the inhibitory domain of the Oct-2 cellular transcription factor. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Functional interaction between the HIV-1 Tat transactivator and the inhibitory domain of the Oct-2 cellular transcription factor.

AIDS. 1996 Oct;10(12):1323-9. Unique Identifier : AIDSLINE MED/97057721
Liu YZ; Lania L; Latchman DS; Department of Molecular Pathology, University College London Medical; School, UK.

Abstract: OBJECTIVES: To examine the interaction of the HIV Tat protein and the inhibitory domain of the cellular transcription factor Oct-2. DESIGN: HIV reporter plasmids were co-transfected with expression vectors encoding wild-type and mutant Tat proteins and vectors encoding the inhibitory domain either alone or linked to a DNA-binding domain. METHODS: The activity of the different reporters was compared in the presence or absence of Tat or the inhibitory domain, or both. RESULTS: In the presence of the Tat protein, the Oct-2 inhibitory domain enhances the activation of Tat-responsive promoters by Tat. This effect is not observed when either the inhibitory domain or Tat cannot bind to the target gene, but is observed when one or both of the factors can bind. No activation is observed when the Oct-2 domain is co-transfected with Tat mutants that lack the Tat activation domain, indicating that the Oct-2 domain cannot substitute for the Tat activation domain. CONCLUSION: These data indicate that the Oct-2 inhibitory domain can functionally interact with Tat to form a complex with enhanced transactivating ability.
Keywords: *DNA-Binding Proteins/METABOLISM *Gene Products, tat/METABOLISM *Transcription Factors/METABOLISMKWDdna-bindingproteins/metabolismKWDgeneproducts,tat/metabolismKWDtranscriptionfactors/metabolism
970530
M9751984

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .